As a co-founder and KOSMAS’ CSO, Georg has a life-long commitment to the development of anti-cancer drugs.

After early research on DNA intercalating agents including daunorubicin, he turned to DNA tumor viruses. At the Swiss Cancer Research Institute ISREC and the Cold Spring Harbor Tumor Virus Lab he contributed to our understanding of the important viral oncoprotein T-antigen. Back at ISREC his team cloned and sequenced the gene coding for complement C3, a key component of innate immunity. At the Scripps Research Institute his lab worked on C3-related acute phase plasma proteins and the regulation of their gene expression by mediators of inflammation including Interleukin-6, work contributing to the discovery of transcriptional regulators STAT3 and STAT5. As chairman of Genetics at the University of Erlangen his team worked on pathogenetic mechanisms of leukemias and conceived antibody-derived proteins for the treatment of leukemias, including the patent-protected trilytes, KOSMAS’ business foundation.

Georg earned a doctoral degree in Physics from the University of Paris, France and a PhD degree in Biochemistry from the Friedrich Alexander University of Erlangen-Nuremberg, Germany.